This is a Validated Antibody Database (VAD) review about Rhesus mon.. CD274, based on 33 published articles (read how Labome selects the articles), using CD274 antibody in all methods. It is aimed to help Labome visitors find the most suited CD274 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD274 synonym: programmed cell death 1 ligand 1; programmed cell death ligand 1

BioLegend
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:300; loading ...; fig s1b
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:300 (fig s1b). JCI Insight (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1c
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 1c). Front Immunol (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s5a
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig s5a). Cancer Res (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; mouse; 1:200; loading ...; fig s1a
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on mouse samples at 1:200 (fig s1a). Oncoimmunology (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 4d
BioLegend CD274 antibody (BioLegend, 329708) was used in flow cytometry on human samples (fig 4d). Front Immunol (2018) ncbi
mouse monoclonal (29E.2A3)
  • western blot; human; 1:50; loading ...; fig 1b
BioLegend CD274 antibody (BioLegend, 329708) was used in western blot on human samples at 1:50 (fig 1b). Nat Commun (2018) ncbi
mouse monoclonal (29E.2A3)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 4b
BioLegend CD274 antibody (BioLegend, 329708) was used in flow cytometry on human samples (fig 4b). J Clin Invest (2017) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry - paraffin section; human; 1:100; fig 8
BioLegend CD274 antibody (Biolegend, 329710) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 8). Oncoimmunology (2017) ncbi
mouse monoclonal (29E.2A3)
  • blocking or activating experiments; human; loading ...; fig 6c
In order to implicate retroviral replicating vectors expressing micro30-derived shRNA against Pol II and Pol III as an alternative approach to enhance anti-tumor immunity, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in blocking or activating experiments on human samples (fig 6c). Mol Ther Nucleic Acids (2017) ncbi
mouse monoclonal (29E.2A3)
  • mass cytometry; human; fig s8
BioLegend CD274 antibody (BioLegend, 329702) was used in mass cytometry on human samples (fig s8). Nature (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1d
In order to study a mouse model of anti-human PD-L1 for developing new cancer treatments., BioLegend CD274 antibody (Biolegend, 29E.29A3) was used in flow cytometry on human samples (fig 1d). Sci Rep (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig s4b
BioLegend CD274 antibody (BioLegend, 29E-2A3) was used in flow cytometry on human samples (fig s4b). JCI Insight (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 2c
In order to propose that decidual stromal cells are a cellular source of BAFF for B cells present in decidua during pregnancy, BioLegend CD274 antibody (Biolegend, 329706) was used in flow cytometry on human samples (fig 2c). Sci Rep (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 5d
BioLegend CD274 antibody (Biolegend, 329714) was used in flow cytometry on human samples (fig 5d). Cell (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1a
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 1a). Sci Rep (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:100; fig 5a
In order to investigate the impact of a cancer-specific MUC1 glycoform, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:100 (fig 5a). Nat Immunol (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 4
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 4). Clin Cancer Res (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s1
In order to utilize humanized major histocompatibility class I- and class II-deficient NOG mice to assess the antitumor effect of an anti-programmed death-1 antibody, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig s1). Clin Cancer Res (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; mouse; loading ...; fig 10
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on mouse samples (fig 10). J Clin Invest (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig s6b
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig s6b). Oncotarget (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:40; fig 1
BioLegend CD274 antibody (BioLegend, 329706) was used in flow cytometry on human samples at 1:40 (fig 1). Mol Med Rep (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:200; fig 2
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:200 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (29E.2A3)
  • blocking or activating experiments; human
  • flow cytometry; human; fig 7
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in blocking or activating experiments on human samples and in flow cytometry on human samples (fig 7). J Immunol Methods (2016) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry; human; 1:100
BioLegend CD274 antibody (Biolegend, 329707) was used in immunohistochemistry on human samples at 1:100. Cancer Res (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 6
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig 6). PLoS Pathog (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BioLegend CD274 antibody (BioLegend, 29F.2A3) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 2
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 2). Oncotarget (2015) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry - paraffin section; human; 1:50
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in immunohistochemistry - paraffin section on human samples at 1:50. J Neuroimmunol (2014) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 4
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig 4). Cancer Discov (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (29E.2A3)
BioLegend CD274 antibody (BioLegend, #329702) was used . Cancer Res (2014) ncbi
Articles Reviewed
  1. Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher
  2. Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher
  3. Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher
  4. Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher
  5. Capuano C, Battella S, Pighi C, Franchitti L, Turriziani O, Morrone S, et al. Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. Front Immunol. 2018;9:1031 pubmed publisher
  6. Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher
  7. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  8. Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher
  9. Berthel A, Zoernig I, Valous N, Kahlert C, Klupp F, Ulrich A, et al. Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival. Oncoimmunology. 2017;6:e1286436 pubmed publisher
  10. Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher
  11. Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher
  12. Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher
  13. Martin Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, et al. Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight. 2017;2:e89574 pubmed publisher
  14. Lundell A, Nordström I, Andersson K, Lundqvist C, Telemo E, Nava S, et al. IFN type I and II induce BAFF secretion from human decidual stromal cells. Sci Rep. 2017;7:39904 pubmed publisher
  15. Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167:419-432.e16 pubmed publisher
  16. An L, Gorman J, Stephens G, Swerdlow B, Warrener P, Bonnell J, et al. Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep. 2016;6:33346 pubmed publisher
  17. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
  18. Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher
  19. Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
  20. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  21. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  22. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  23. Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher
  24. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  25. Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
  26. Miranda A, Funes J, Sánchez N, Limia C, Mesa M, Quezada S, et al. Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. Cancer Res. 2015;75:3032-42 pubmed publisher
  27. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  28. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  29. Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed
  30. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  31. Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher
  32. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  33. Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher